Company profile: Precipio
1.1 - Company Overview
Company description
- Provider of cancer diagnostics and personalized medicine, offering hematopathology clinical diagnostic services and SmartPath second-opinion services for treatment plan validation, molecular testing reagents including HemeScreen, Bloodhound BCR-ABL1, and HemeScreen AML, and IV-Cell culture media for multi-cell lineage with simplified workflow and clinical accuracy.
Products and services
- Clinical Services: Delivers high-accuracy hematopathology diagnostics with rigorous quality from a cancer diagnostics reference laboratory, supporting advanced diagnostics and personalized medicine advice, accuracy-focused
- HemeScreen Reagents: Engineers molecular testing technology for hematology diagnostics, delivering a simplified workflow for consistent assays and streamlined steps, workflow-optimized
- SmartPath Services: Supplies second-opinion reviews from specialized experts for treatment plan validation, delivering confirmatory perspectives before finalizing treatment plans, validation-focused
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Precipio
Rakuten Medical
HQ: United States
Website
- Description: Provider of investigational cancer therapies based on the proprietary Alluminox photoimmunotherapy platform, which combines a drug with targeting moieties and a light-activating device using non-thermal illumination to selectively target cancer cells; includes ASP-1929, an Alluminox-developed drug with dye-conjugated targeting moieties, approved in Japan for treating certain cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rakuten Medical company profile →
CoRegen
HQ: United States
Website
- Description: Provider of SRC-3 and Treg-focused therapies: SRC-3 KO Treg Therapy that engineers Treg cells to infiltrate and destroy tumors; an SRC-3 small molecule inhibitor that blocks transcriptional activity to inhibit cancer growth and boost immune response; an SRC-3 small molecule enhancer to reduce inflammation and improve tissue repair in myocardial infarction and stroke; and Treg engineering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoRegen company profile →
Amcure
HQ: Germany
Website
- Description: Provider of peptide-based compounds in clinical development for the treatment of highly metastatic forms of squamous cancer; a privately held spin-off from the Karlsruhe Institute of Technology established in 2012 and supported by a grant from the German Federal Ministry of Education and Research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amcure company profile →
Applied Proteomics
HQ: United States
Website
- Description: Provider of protein biomarker discovery solutions, including SimpliPro Colon Test—a blood test for healthcare providers to aid colorectal health assessment by measuring 11 protein markers associated with colorectal cancer and advanced adenoma—plus a mass-spectrometry (tandem LCMS) proteomics platform, proprietary workflow management system, and advanced visualization tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied Proteomics company profile →
Theragnostics
HQ: United Kingdom
Website
- Description: Provider of diagnostic and therapeutic agents, aiming to deliver a complete portfolio of products to transform patient care from initial diagnosis to therapy; established as Theragnostics Ltd in 2015, with a US presence via Theragnostics Inc (2016) and an office in Boston, MA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theragnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Precipio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Precipio
2.2 - Growth funds investing in similar companies to Precipio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Precipio
4.2 - Public trading comparable groups for Precipio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →